Patents by Inventor Alison Nagle

Alison Nagle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic combinations using IGF1R pathway inhibitors, and methods to predict anti-IGF1R therapeutic efficacy
    Patent number: 11548939
    Abstract: Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. Also disclosed herein are methods to treat a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 10, 2023
    Assignee: University Of Pittsburgh-Of The Commonwealth System Of Higher Education
    Inventors: Adrian Lee, Alison Nagle, Steffi Oesterreich
  • THERAPEUTIC COMBINATIONS USING IGF1R PATHWAY INHIBITORS, AND METHODS TO PREDICT ANTI-IGF1R THERAPEUTIC EFFICACY
    Publication number: 20190315847
    Abstract: Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. Also disclosed herein are methods to treat a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.
    Type: Application
    Filed: February 26, 2019
    Publication date: October 17, 2019
    Inventors: Adrian Lee, Alison Nagle, Steffi Oesterreich